Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heartbeam, Inc. - Common Stock (NQ:BEAT)

1.520 -0.060 (-3.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Heartbeam, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures Two New Patents Advancing 3D ECG and Cardiac Monitoring Technology
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
Via ACCESS Newswire
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025
From HeartBeam, Inc.
Via Business Wire
HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reported Q1 2025 Results, Advanced Toward Commercialization Following VALID-ECG Study Success
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Reports First Quarter 2025 Results
From HeartBeam, Inc.
Via Business Wire
Two New U.S. Patents Bring Total to 20 Issued Worldwide, Cementing Company Leadership in Cardiac Monitoring Innovation for 12-Lead ECG Synthesis Technology: HeartBeam, Inc. (Nasdaq: BEAT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
From HeartBeam, Inc.
Via Business Wire
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property Product Safety
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
From HeartBeam, Inc.
Via Business Wire
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Partner to Advance Remote ECG Monitoring
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam Announces Exercise and Closing of Underwriter’s Over-Allotment Option for Public Offering of Common Stock
From HeartBeam, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.